Ned Pagliarulo

While J&J expects tariffs will cost it $400 million this year, the company maintained its earnings estimate and upped its sales guidance for 2025.

Commissioner Martin Makary said the agency would, whenever possible, restrict drug company employees from participating as industry representatives on advisory committees.

The company’s CEO said he’s had “productive discussions” with Trump administration officials on a recently launched trade probe.

The company has predicted that Imaavy — now approved for myasthenia gravis — could eventually earn more than $5 billion in annual sales at its peak.

Drugmaker executives have projected confidence they can mitigate the impact of any levies Trump imposes on the industry. Yet they're adjusting inventory and production nonetheless.

While updated study results confirmed the drug lowers a target protein, the therapy's effect on clinical outcomes was less clear-cut.

The maker of Ozempic and Wegovy expects lower sales and profit growth this year despite recent victories against compounders.

The proposal would see the HHS set price targets other countries pay for certain medicines, kicking off a round of discussions with substantial ramifications for drugmakers. It’s likely to be challenged in court, however.

Lars Fruergaard Jørgensen will step down after eight years helming the Danish drugmaker, shares of which have lost more than half their value over the past 12 months.